Predict your next investment

Advisory
FINANCE | Investment Banking
rmglobal.com

See what CB Insights has to offer

Investments

7

Portfolio Exits

1

Funds

1

About RM Global Partners

RM Global Partners is an investment banking and strategic advisory firm.

RM Global Partners Headquarter Location

880 Third Avenue 16th Floor

New York, New York, 10022,

United States

212-792-6966

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

RM Global Partners Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

RM Global Partners Rank

Latest RM Global Partners News

ImmPACT Bio Grabs $18M Series A Financing Round

Aug 20, 2020

ImmPACT Bio USA, a company founded in the FutuRx incubator located in Ness Ziona, Israel, developing novel cell therapies for treating cancer, today announced the closing of a US$ 18 million equity financing round. The financing included OrbiMed, Johnson & Johnson Innovation - JJDC, Inc., Takeda Ventures, Inc., RM Global Partners (RMGP) BioPharma Investment Fund, Novartis Venture Fund, Bukwang Pharmaceutical, Hayan Health Networks, Inc., and JVC Investment Partners. ImmPACT Bio USA Inc. is developing a novel set of engineered T-cell therapeutics that target loss of genes in solid tumors. The company was founded based on the insights of Prof. Gideon Gross (Migal Research Institute), who collaborated with Prof. Zelig Eshhar to design the first Chimeric Antigen Receptor technologies for T-cells (CAR T). While CAR-T drugs have provided meaningful breakthroughs for the treatment of some hematologic malignancies, little progress has been made in applying the technology to solid tumors. Such diseases are rarely characterized by the over-expression of tumor-selective antigens, but genomic analyses have revealed many mechanisms for loss of expression. Founder Prof. Gideon Gross explains ImmPACT's origins by observing, "Engineered cells have progressed tremendously in lymphomas and leukemias, in large part because lymphocytes have very selective targets. We will need new targeting strategies to tackle solid tumors, as few selective targets have been discovered, and antigens are almost always shared by indispensable tissues." Prof. Gross ultimately realized that, "Many solid tumors demonstrate genetic losses due to abnormal chromosomal maintenance - a fact that can be utilized to design new types of cellular immuno-oncology drugs." "We have built a world-class team and a promising pipeline to realize Prof. Gross' vision of targeting loss-of-gene features of solid tumors. We look forward to working with our investors to advance this pipeline and make the company a success," said Rick Kendall, Ph.D., CEO of ImmPACT Bio USA Inc. About ImmPACT Bio ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The company was founded based on the research of Prof. Gideon Gross of the Migal Research Institute and has been incubated in the FutuRx incubator since 2017. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.

RM Global Partners Investments

7 Investments

RM Global Partners has made 7 investments. Their latest investment was in ImmPACT Bio as part of their Series B on January 1, 2022.

CBI Logo

RM Global Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

1/20/2022

Series B

ImmPACT Bio

$111M

No

15

8/5/2020

Series A

Subscribe to see more

$99M

Subscribe to see more

10

11/13/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/29/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

2/20/2019

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/20/2022

8/5/2020

11/13/2019

5/29/2019

2/20/2019

Round

Series B

Series A

Series A

Series B

Series B

Company

ImmPACT Bio

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$111M

$99M

$99M

$99M

$99M

New?

No

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

15

10

10

10

10

RM Global Partners Portfolio Exits

1 Portfolio Exit

RM Global Partners has 1 portfolio exit. Their latest portfolio exit was BiomX on October 28, 2019.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/28/2019

Reverse Merger

$99M

7

Date

10/28/2019

Exit

Reverse Merger

Companies

Valuation

$99M

Acquirer

Sources

7

RM Global Partners Fund History

1 Fund History

RM Global Partners has 1 fund, including RMGP Biopharma Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/8/2019

RMGP Biopharma Fund

$64M

5

Closing Date

4/8/2019

Fund

RMGP Biopharma Fund

Fund Type

Status

Amount

$64M

Sources

5

RM Global Partners Team

5 Team Members

RM Global Partners has 5 team members, including current Managing Director, Yaron Breski.

Name

Work History

Title

Status

Yaron Breski

Managing Director

Current

Bruce E Roberts

Managing Director

Current

Bruce E. Roberts

Managing Director, Owner

Current

Jack Springer

Managing Director

Current

Breski Yaron

Managing Director

Current

Name

Yaron Breski

Bruce E Roberts

Bruce E. Roberts

Jack Springer

Breski Yaron

Work History

Title

Managing Director

Managing Director

Managing Director, Owner

Managing Director

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.